DECN ANNOUNCES 2018 BUSINESS FOCUS -- NEW PRODUCTS, CONCLUSION TO J&J LITIGATION & NEW ADDITION OF HYBRID PRIVATE LABEL MODEL
03 Gennaio 2018 - 3:55PM
InvestorsHub NewsWire
DECISION DIAGNOSTICS ("DECN") ANNOUNCES 2018
BUSINESS FOCUS THROUGH THE INTRODUCTION OF NEW PRODUCTS, POSITIVE
CONCLUSION TO THE J&J LITIGATION, AND HYBRID PRIVATE LABEL
BUSINESS MODEL
LOS ANGELES, CA -- January 3, 2018 --
InvestorsHub NewsWire -- Decision Diagnostics Corp. (OTC
PINK: DECN) is a manufacturer, quality plan administrator, FDA
registered medical device customer support organization, and
exclusive worldwide sales and regulatory process agent for the
GenUltimate!™ ("Sunshine") diabetes test strip, the new
internationally launched GenSure!™ ("Feather") diabetes test strip,
and the clinical trial ready GenChoice!™ ("Ladybug") diabetes test
strip, as well as three other unique test strips and meters in
development, including our panacea strip and meter system the
highly innovative GenPrecis!™ and its first collateral asset,
our GenAccord!™ multiple-egress test strip. Today, DECN previews
its plans and expected outcomes for 2018.
J&J Litigation
DECN has been locked in confrontational patent
litigation with two divisions of Johnson & Johnson (NYSE: JNJ),
almost continuously, since September 2011. The company was
victorious as a Defendant in the first three suits and received a
payout at their conclusion. The current lawsuit positions two
divisions of DECN as plaintiffs having filed suit against
J&J for infringement of the company’s patented test strip
technology. As anticipated, J&J has employed the
identical deceptive tactics and delaying strategies they embraced
during the prior litigations. They failed to affect the final
outcome in the past and it is expected that they will fail once
again. The company’s legal positions are strong and are
supported by the rulings made by higher courts in the first three
cases. If necessary, the company is fully prepared, both legally
and financially, to litigate until J&J has exhausted their
final appeal. However, the company believes that the strength of
its position will ultimately drive a negotiated settlement.
Keith Berman, CEO of
Decision Diagnostics Corp commented, “J&J, through their
superior resources and “scorched earth” legal strategy, has exacted
heavy tolls on our business operations. However, through this
adversity the company has discovered its footing as a legitimate
competitor in a highly regulated and heavily litigious environment.
We are now fortified and fully prepared to successfully engage as
we introduce new products and continue to expand our base of
business.”
New Product Introductions
2018 is expected to become a seminal year for
DECN. It begins with the marketing of its launched GenSure!™
diabetic test strip, targeted for the patient population across the
developing markets. The company will then, in rapid succession,
introduce three new products, the GenChoice!™ test strip for
worldwide distribution, GenPrecis!™ test strip and Precise meter,
and the GenAccord!™ multiple-egress test strip that capitalizes on
the GenPrecis!™ “full spread electro-chemistry technology.”
This intense activity begins January 15, 2018 with the global
introduction of the GenSure!™ test strip. Following shortly
thereafter, at the end of January 2018, the commencement of
clinical trials for the GenChoice! test strip should culminate with
the filing of 510K application filing for market clearance with the
U.S. FDA in late February . International sales of
GenChoice!™ are expected to begin in March 2018.
Additionally, the company intends to finalize
its testing of the GenPrecis!™ test strip by January 28, and the
GenPrecis!™ Precise meter by February 28. This
GenPrecis!™ test strip is now compatible
with two legacy meters sold internationally.
Mr. Berman continued, “Our one overriding goal
has been to create a brand that is unique and superior to what the
industry has thus far produced. DECN is not, and will never be,
another uninspired producer of imitation products. We are
committed to being creative, nimble and aggressive throughout our
current and future product line.”
Hybrid
Private Label Model
We have registered with the U.S. USPTO and the
U.S. FDA two new product family names; Alltara!™ and
Advant!™. These brands will become those licensed to big box
retailers as their own exclusive private label. We anticipate
registering more trade family names as our “big box” plan proceeds.
The company is currently completing the private label packaging for
the GenUltimate!™ product, now named Alltara!™
ultimate. This expansion is expected to
be followed by Alltara!™ choice and then
by Alltara!™ precis. First
deliveries of Alltara!™ ultimate are
expected in 2Q 2018. This brand will not be sold by any
direct to patient distributors. First postings of product images,
with disclaimers, if any, will be placed on the company’s web sites
in coming days. The company will provide a full discussion of this
business model in its 2017 Annual Report.
Mr. Berman concluded,
“It is exhilarating when large big box retailers pursue our
products for placement on their shelves. The years of litigation
and struggle have been finally rewarded with the collapse of the
retail barriers erected by J&J to our product placement in the
retail marketplace. Now that those obstacles are crumbling, we
intend to capitalize on the opportunity with our existing products
and our eagerly anticipated bevy of new product
introductions.“
ABOUT DECISION DIAGNOSTICS
CORP.
Decision Diagnostics Corp. is the leading
manufacturer and worldwide distributor of diabetic test strips
engineered to operate on legacy glucose meters. DECN's products are
designed to operate efficiently and less expensively on certain
glucose meters already in use by almost 7.2 million diabetics
worldwide. With new inspired technology already in the final stages
of development, ready for market, or in final clinical trials, DECN
products are already or set to compete on a worldwide scale with
legacy manufacturers currently selling to 66%+ percent of a $12
billion market.
Forward-Looking
Statements:
This release contains the company's
forward-looking statements which are based on management's current
expectations and assumptions as of January 2, 2018, regarding the
company's business and performance, its prospects, current factors,
the economy, and other future conditions and forecasts of future
events, circumstances, and results.
CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
info@decisiondiagnostics.com
www.genultimate.com
www.pharmatechdirect.com
Grafico Azioni Decision Diagnostics (CE) (USOTC:DECN)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Decision Diagnostics (CE) (USOTC:DECN)
Storico
Da Nov 2023 a Nov 2024